Yingli Pharma Doses First Patient in Linperlisib Phase II Trial for PTCL
US-based Yingli Pharma, which targets the China and US drug markets, has dosed the first...
Junshi Biosciences Plans USD 572M Private Placement to Fund Drug R&D and Expansion
China’s Shanghai Junshi Biosciences Co., Ltd (SHA: 688180, HKG: 1877) announced plans to raise up...
CanSino, Livzon Win China EUAs for COVID-19 Booster Vaccines
China-based vaccine makers CanSino Biologics (HKG: 6185) and Livzon Pharmaceutical Group Inc. (HKG: 1513) have...
AWS Partners with Zhongshan to Launch Smart Manufacturing and Biomedical Digital Center
Amazon Web Services (AWS) and Zhongshan’s Bureau of Commerce announced a partnership at the China...
BoomRay Pharmaceuticals Raises USD 43M in Series A for RDC Pipeline Expansion
China’s BoomRay Pharmaceuticals, a specialist in radionuclide drug conjugates (RDCs), reportedly raised nearly RMB 300...
Zelgen Biopharmaceuticals’ Jacktinib Wins FDA Approval for Severe Alopecia Areata
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) secured U.S. FDA approval to launch a clinical...
Jacobio Pharmaceuticals Doses First Patient in JAB-BX102 Phase I/IIa Trial for CD73-Targeted Cancer Therapy
China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) announced the first patient dosed in a...
Northeast Pharma Licenses MedAbome’s MAb11-22.1 for ADC and CAR-T Development
China’s Northeast Pharmaceutical Co., Ltd (SHE: 000597) has signed a licensing agreement with U.S.-based MedAbome...
Alphamab Oncology Highlights KN046, KN026 Advances at ESMO 2022
China’s Alphamab Oncology (HKG: 9966) will present updated clinical data for its bispecific antibody candidates...
AstraZeneca’s Farxiga Wins China Approval for Chronic Kidney Disease
UK pharma giant AstraZeneca (AZ, NASDAQ: AZN) announced a new approval for Farxiga (dapagliflozin), its...
Innovent Biologics Doses First Patient in Higher-Dose Mazdutide Obesity Trial
China’s Innovent Biologics, Inc. (HKG: 1801) announced that the first participant has been dosed in...
Shanghai Pharma’s CD20 Antibody Advances to Primary Nephropathy Trial After NMPA Approval
China’s Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products...
Walvax Biotech Wins NMPA Approval for mRNA and Recombinant COVID-19 Vaccines
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has received clinical trial approvals from the National...
Medim Science Raises Funds for Macrophage-Targeting Biologics in Cancer Therapy
Hangzhou-based Medim Science, China’s first pharma firm focused on macrophage-targeting biologics, has reportedly raised tens...
China’s Pharmaceutical Industry Sees Revenue Decline Amid Export Shifts
China’s pharmaceutical manufacturing sector reported a 1.8% year-on-year (YOY) revenue decline to RMB 1.6 trillion...
Tibet Duo Rui and Nanjing Heron Forge Pharmaceutical Collaboration in China
China-based Tibet Duo Rui Pharmaceutical Co., Ltd and Nanjing Heron Pharmaceutical Science and Technology Co.,...
CARsgen Therapeutics Launches GMP Manufacturing for CAR-T Cell Therapies in North Carolina
China’s CARsgen Therapeutics Holdings Ltd (HKG: 2171), a chimeric antigen receptor (CAR)-T cell specialist, has...
MegaRobo and Danaher Life Sciences Partner on Lab Automation in China
Beijing-based MegaRobo Technologies, a robotics and AI firm in life sciences, has partnered with Danaher...
Hengrui Medicine’s HRG2101 Inhaler Wins NMPA Approval for IPF Clinical Trial
China’s Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has received approval from the National Medical...
U Protech Secures Angel Financing for PROTAC and Molecular Glue Drug Pipeline
U Protech, a Hangzhou-based biotech focused on next-generation protein degradation therapies, has raised tens of...